HYPERTHYROIDISM AND GRAVES' DISEASE: OPHTHALMOLOGICAL MANIFESTATIONS AND SURGICAL TREATMENT.
PDF

Palavras-chave

Hyperthyroidism,

Como Citar

Santos, L. B. M., Costa, T. da, Barros, L. A. A. C. de, Almeida, P. da C. S. de, Oliveira, G. N., Amaro, L. L., Cruz, R. A., Alencar, D. S., Rodrigues, M. do C., Correa, S. M., Martins, P. F. R., & Ribeiro, P. H. R. (2024). HYPERTHYROIDISM AND GRAVES’ DISEASE: OPHTHALMOLOGICAL MANIFESTATIONS AND SURGICAL TREATMENT. Brazilian Journal of Implantology and Health Sciences, 6(8), 1106–1118. https://doi.org/10.36557/2674-8169.2024v6n8p1106-1118

Resumo

Introduction: Hyperthyroidism, characterized by the excessive production of hormones by the thyroid gland, can lead to various systemic complications, including ophthalmological manifestations such as Graves' Orbitopathy (GO). Graves' Disease, one of the main causes of hyperthyroidism, is often associated with these ocular complications, which include ocular protrusion, diplopia, and periorbital swelling. Surgical treatment, including total or subtotal thyroidectomy, emerges as an option to control the progression of hyperthyroidism and improve associated ophthalmological symptoms. **Objective**: To analyze the ophthalmological manifestations of hyperthyroidism and Graves' Disease, as well as evaluate the effectiveness of surgical treatment in managing these complications. **Methodology**: The review followed the PRISMA checklist to ensure rigor and transparency. Searches were conducted in PubMed, Scielo, and Web of Science databases using five descriptors: "Hyperthyroidism," "Graves' Disease," "Graves' Orbitopathy," "Surgical Treatment," and "Ophthalmological Manifestations." Inclusion criteria encompassed articles published in the last 10 years, studies focused on surgical treatment for GO, and works explicitly addressing the ophthalmological manifestations of Graves' Disease. Exclusion criteria included studies that did not discuss surgical treatment, non-peer-reviewed articles, and publications older than a decade. **Results**: The analysis revealed that Graves' Orbitopathy frequently manifests with symptoms such as ocular protrusion, diplopia, and periorbital edema, significantly impacting patients' quality of life. Thyroidectomy proved effective in reducing hormone levels, resulting in symptomatic improvements for many patients. However, outcomes varied, and surgical intervention was not always associated with complete resolution of ophthalmological manifestations. **Conclusion**: Surgical treatment of hyperthyroidism and Graves' Disease can provide significant relief from ophthalmological manifestations, though it does not guarantee complete resolution of symptoms. Surgery should be considered within a multidisciplinary context, taking into account the severity of ocular symptoms and response to conservative treatment. The review highlighted the need for integrated treatment strategies to optimize outcomes for patients with ophthalmological complications associated with hyperthyroidism and Graves' Disease.

https://doi.org/10.36557/2674-8169.2024v6n8p1106-1118
PDF

Referências

Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304. doi: 10.1016/j.ecl.2021.12.004.

Bobanga ID, McHenry CR. Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy. Best Pract Res Clin Endocrinol Metab. 2019 Aug;33(4):101319. doi: 10.1016/j.beem.2019.101319.

Elia G, Fallahi P, Ragusa F, Paparo SR, Mazzi V, Benvenga S, Antonelli A, Ferrari SM. Precision Medicine in Graves' Disease and Ophthalmopathy. Front Pharmacol. 2021 Oct 28;12:754386. doi: 10.3389/fphar.2021.754386.

Subramanian PS, Cho RI, Kahana A. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol. 2023 Nov 1;34(6):487-492. doi: 10.1097/ICU.0000000000000997.

Roos JCP, Murthy R. Update on the clinical assessment and management of thyroid eye disease. Curr Opin Ophthalmol. 2019 Sep;30(5):401-406. doi: 10.1097/ICU.0000000000000596.

Oeverhaus M, Winkler L, Stähr K, Daser A, Bechrakis N, Stöhr M, Chen Y, Eckstein A. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis. Front Endocrinol (Lausanne). 2023 Apr 4;14:1160172. doi: 10.3389/fendo.2023.1160172.

Al-Qadi M, Hussain A. Influence of orbital decompression on upper eyelid retraction in Graves' orbitopathy: a systematic review and meta-analysis. Orbit. 2024 Aug;43(4):549-554. doi: 10.1080/01676830.2023.2248621.

Kinori M, Godfrey KJ, Whipple KM, Kikkawa DO, Granet DB. Refractive changes following corrective surgery for thyroid-related orbitopathy. J AAPOS. 2017 Feb;21(1):67-68. doi: 10.1016/j.jaapos.2016.09.021.

Lim NC, Sundar G, Amrith S, Lee KO. Thyroid eye disease: a Southeast Asian experience. Br J Ophthalmol. 2015 Apr;99(4):512-8. doi: 10.1136/bjophthalmol-2014-305649.

Wu CY, Elner VM, Kahana A. Severe Pediatric Thyroid Eye Disease: Surgical Case Series. Ophthalmic Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S186-S188. doi: 10.1097/IOP.0000000000000585.

Penta L, Muzi G, Cofini M, Leonardi A, Lanciotti L, Esposito S. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy? Int J Environ Res Public Health. 2019 Jan 8;16(1):155. doi: 10.3390/ijerph16010155.

Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015 Mar;133(3):290-6. doi: 10.1001/jamaophthalmol.2014.5103.

Ben Simon GJ, Katz G, Zloto O, Leiba H, Hadas B, Huna-Baron R. Age differences in clinical manifestation and prognosis of thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2301-8. doi: 10.1007/s00417-015-3156-2.

Woo YJ, Kim JW, Yoon JS. Preoperative clinical features of reactivated of Graves' orbitopathy after orbital decompression. Eye (Lond). 2017 Apr;31(4):643-649. doi: 10.1038/eye.2016.304.

Zhao J, Hodgson NM, Chang JR, Campbell AA, McCulley TJ. Thyroid Eye Disease-Related Epiblepharon: A Comparative Case Study. Asia Pac J Ophthalmol (Phila). 2020 Jan-Feb;9(1):44-47. doi: 10.1097/01.APO.0000617916.50176.b2.

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Luan Bernardino Montes Santos, Thelma da Costa, Layla Azevedo Alencastro Cupertino de Barros, Pedro da Costa Siqueira de Almeida, Gabriel Nojosa Oliveira, Lara Lacerda Amaro, Rayane Alves Cruz, Dayanne Soares Alencar, Matheus do Carmo Rodrigues, Stefanny Machado Correa, Pedro Felipe Rezende Martins, Pedro Henrique Rodrigues Ribeiro

Downloads

Não há dados estatísticos.
1 1